Costco will begin selling weight-loss drugs Ozempic and Wegovy in the United States, reported The New York Times. Costco members with a prescription will pay $499 out of pocket for a four-week supply of either medication.

“That cost is about half of the list price for Ozempic, and about two-thirds less than that of Wegovy. The list price is the ‘sticker price’ a company sets before any discounts, rebates or other reductions are given to wholesalers or pharmacy benefit managers,” the Times wrote. “Costco’s executive members and Costco Citibank Visa card holders will get an additional 2% discount.”

“We continue to find new ways to make access to our medicines more convenient, meeting people where they are,” a Novo Nordisk spokeswoman said in a statement.

Per the report, Novo Nordisk already sells a monthly supply of Ozempic and Wegovy for $499, each separately, at its direct-to-consumer website, and it offers the same discount at CVS and Walmart.

Last month, NACS Daily reported that Costco reported a year over year increase of 3.2% in visits in Q2 2025.

About seven million Americans take a GLP-1 drug, and Morgan Stanley estimates that the number of U.S. users could expand to 24 million by 2035. From 2019 to 2023, there was an over 700% increase in the number of new GLP-1 prescriptions for patients without diabetes who are overweight or obese, according to a study cited by the Times.

Numerator data shows that GLP-1 users’ c-store trips are down when it comes to more indulgent foods, including RTD coffee, frozen desserts, chips, alcohol and candy. But trips have increased when it comes to options that support their health, such as prebiotic and probiotic soda, performance shakes, yogurt, meat snacks and kombucha. Read about how you can attract GLP-1 consumers in the June 2025 issue of NACS Magazine feature “Targeting the GLP-1 Shopper.”

Attending the NACS Show? Check out the Education Session “GLP-1s and the New Snack Equation,” which takes place October 14 at 3:15 p.m. CST.